Analyst trust grows for Richter
Hungarian pharma major Richter is strengthening its market positions thorough regional acquisitions.
Hungary’s Richter Gedeon Nyrt, Eastern Europe’s biggest drugmaker, is strengthening its market share through the acquisition of Poland’s Polpharma and Russia’s Akrikhin, UBS said. Richter’s shares gained more than 30% compared to previous months’ results.
Erste and UBS increased their recommendations of shares, from sell to hold. Richter shares rose 1.6%, to Ft 39,800 in Budapest. Richter expects further 18.2% increase on its eastern markets of the former soviet states, while expects only some 3% decrease in local income and a slight start in increasing volume. Recommendations to Richter: Erste-buy-47,600; UBS-hold-42,400; Deutsche Bank-sell-35,000; KBC-buy-44,459; ING-hold-42,500; Credit Suisse-44,000. (NG 13)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.